Head-to-head study backs Teleflex UroLift system against Boston Scientific’s Rezūm
A new head-to-head study, CLEAR, found that Teleflex's UroLift system for benign prostatic hyperplasia (BPH) outperformed Boston Scientific's Rezūm water vapor therapy in early patient satisfaction and sexual function. The study, presented at the European Association of Urology Congress, also showed better catheter independence and fewer instances of discomfort with UroLift. Teleflex emphasizes that these findings provide critical insights for informed treatment decisions for BPH.
Teleflex (TFX) Fell on Spin-Off Announcements
The article discusses the impact of Teleflex (TFX) falling due to spin-off announcements. Further details on the spin-off and its specific financial implications are not provided in the given content.
Teleflex earnings loom as leadership, strategy shift collide
Teleflex Incorporated is set to announce its fourth-quarter results amid a leadership transition and a significant $2 billion portfolio overhaul. Analysts anticipate earnings of $3.79 per share on revenue of $925.4 million as the company prepares to divest several businesses and focus on vascular, interventional, and surgical markets. Investors are closely watching for signs of stabilization in core operations and updates on capital allocation plans, including a $1 billion share repurchase program.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) shares rose 2.03% to $105.86 on Tuesday, outperforming the broader market. This gain broke a two-day losing streak for the stock, as the S&P 500 and Dow Jones Industrial Average also saw slight increases.
Teleflex to Host Q4 2025 Earnings Call on February 26, 2026
Teleflex (NYSE: TFX) will host a conference call on February 26, 2026, at 8:00 a.m. Eastern Time to discuss its Q4 2025 financial results and operational updates. Investors can pre-register for dial-in information or access a live audio webcast on the company’s website, with an audio replay available from 11:00 a.m. ET on the same day. Teleflex, a global provider of medical technologies, aims to ensure transparent communication regarding its commitment to innovation in healthcare.
Teleflex Announces Fourth Quarter 2025 Earnings Conference Call Information
Teleflex Incorporated has announced details for its fourth quarter 2025 earnings conference call and operational update. The call is scheduled for Thursday, February 26, 2026, at 8:00 a.m. Eastern Time, with options for pre-registration dial-in or live audio webcast through teleflex.com. An audio replay will also be available on the company's website or by telephone later that day.
Public Sector Pension Investment Board Has $23.03 Million Stock Position in Teleflex Incorporated $TFX
The Public Sector Pension Investment Board increased its stake in Teleflex Incorporated (NYSE:TFX) by 24.9% in Q3, now holding 188,208 shares valued at $23.03 million. Other institutional investors also adjusted their positions in the medical technology company, which is currently trading near its 1-year low. Analysts have a consensus "Hold" rating for Teleflex, with an average price target of $139.00.
Teleflex Inc.: The Quiet Medtech Workhorse Powering the Future of Minimally Invasive Care
Teleflex Inc. is a critical medtech company that underpins modern minimally invasive care with its product ecosystem in vascular access, anesthesia, and interventional tools. The company focuses on safety, simplicity, and standardization, offering solutions that reduce complications and improve efficiency in hospitals. Its competitive edge lies in clinical nuance, workflow-oriented kits, and economic benefits through reduced downstream complication costs, making it an attractive prospect for investors seeking reliable, procedure-linked revenue.
Laryngeal Mask Market Is Going to Boom |• Ambu A/S • Teleflex Incorporated
Worldwide Market Reports has published an in-depth research study on the "Laryngeal Mask Market Size and Forecast 2026-2033," analyzing by manufacturers, regions, product types, and applications. The report utilizes both primary and secondary research methods, offering comprehensive coverage of market drivers, growth opportunities, restraints, and challenges. It includes insights into competitive landscapes, regional performance, revenue forecasts, and segmentation analysis, highlighting key players like Ambu A/S and Teleflex Incorporated.
Needle Holder Market Is Going to Boom | Teleflex Incorporated • Smith & Nephew • Conmed Corporation
Coherent Market Insights has released a comprehensive research report on the Needle Holder Market, forecasting substantial growth between 2026 and 2033. The report analyzes key market trends, drivers, challenges, and the competitive landscape, covering market size, revenue, and CAGR. It also identifies top companies, market segmentation by product type and region, and provides strategic insights for businesses.
Teleflex Inc (TFX) Shares Gap Down to $104.71 on Feb 9
Teleflex Inc (TFX) shares dropped 3.42% to $104.71 on Feb 9, trading significantly below its 52-week high but slightly above its 52-week low. Analysts forecast an average target price of $135.22, implying a 29.14% upside, while GuruFocus estimates a fair value of $286.34, suggesting a 173.46% upside. The consensus brokerage recommendation for TFX is "Hold."
Teleflex Inc.: The Quiet Hardware Powerhouse Behind Modern Minimally Invasive Care
Teleflex Inc. is highlighted as a critical, albeit quiet, player in modern healthcare, providing essential hardware like catheters and surgical tools for minimally invasive procedures. The article details its product portfolio, competitive landscape against rivals like BD, Boston Scientific, and Medtronic, and its strong market position driven by clinical reliability, workflow optimization, and alignment with healthcare trends. Investors should note Teleflex's stock performance is closely tied to procedure volume growth, adoption of minimally invasive systems like UroLift, and margin resilience, positioning it as an understated yet intriguing player in the medtech sector.
Teleflex Stock In Focus: Steady Climber, Quiet Catalyst – Is This Medtech Sleeper Still A Buy?
Teleflex's stock has quietly outperformed the broader medtech sector over the past year, exhibiting steady growth despite market volatility. The company recently reported reassuring quarterly earnings, reaffirmed its full-year outlook, and continues to receive "Buy" ratings from Wall Street analysts who appreciate its diversified portfolio, incremental innovation, and disciplined financial management. This article explores Teleflex's investment performance, recent catalysts, strategic DNA, and future prospects, suggesting it remains a compelling option for long-term investors.
Teleflex CEO Exit And Legal Review Reshape Governance Risk For Investors
Pomerantz LLP has launched an investigation into Teleflex (NYSE:TFX) following the abrupt departure of CEO Liam Kelly, raising concerns about potential securities violations or unlawful business practices. This leadership change and legal scrutiny increase governance and disclosure risk for investors, especially as the medical technology company navigates softer demand and integrates acquisitions. Shareholders will be watching how the board addresses succession, communicates with the market, and resolves the investigation.
Teleflex Stock Slides 39% in a Year, but This $8.5 Million Buy Signals a Contrarian Bet
Despite a significant 39% drop in Teleflex (NYSE:TFX) stock over the past year, Tejara Capital Ltd has made a substantial contrarian investment, purchasing 69,700 additional shares valued at approximately $8.5 million. This move increased Tejara's stake in Teleflex to 2.23% of its 13F assets under management, signaling confidence in the medical device company amid its ongoing business transition and underperformance relative to the S&P 500. The article highlights Teleflex's recent revenue growth and adjusted EPS expectations, suggesting a resilient business model focused on single-use medical devices for critical care.
Teleflex CEO Exit And Legal Review Reshape Governance Risk For Investors
Teleflex is currently under investigation by Pomerantz LLP for potential securities violations following the abrupt departure of its Chairman, President, and CEO, Liam Kelly. This leadership change and legal scrutiny are significant for investors, raising questions about board oversight, disclosure, and the company's long-term capital allocation. The situation highlights increased governance and disclosure risk, potentially impacting Teleflex's valuation during a period of softer demand and ongoing acquisitions.
Teleflex CEO Exit And Legal Review Reshape Governance Risk For Investors
Pomerantz LLP has launched an investigation into Teleflex (NYSE:TFX) following the sudden departure of its Chairman, President, and CEO, Liam Kelly. This leadership change and legal scrutiny create significant governance and disclosure risks for the medical technology company. Investors are now left to monitor how the board clarifies succession and addresses the investigation amidst existing challenges in demand and integration of past acquisitions.
Is Teleflex (TFX) Starting To Look Interesting After Extended Share Price Weakness?
Teleflex (TFX) has experienced significant share price weakness over the past several years. A Discounted Cash Flow (DCF) analysis suggests the stock is currently overvalued by 26.6% compared to its intrinsic value, while a Price-to-Sales (P/S) ratio analysis indicates it could be undervalued. Investors are encouraged to use interactive "Narratives" to explore different valuation perspectives based on their own assumptions about the company's future performance.
Thrivent Financial for Lutherans Boosts Stock Holdings in Teleflex Incorporated $TFX
Thrivent Financial for Lutherans significantly increased its stake in Teleflex Incorporated (NYSE:TFX) during the third quarter of 2025, purchasing an additional 506,796 shares and now owning a total of 550,449 shares valued at $67.35 million. Despite this substantial institutional investment, Wall Street analysts currently hold a "Hold" consensus rating for Teleflex, with a mixed distribution of Buy, Hold, and Sell ratings and an average target price of $139. The company reported strong Q3 earnings, exceeding estimates with $3.67 EPS and $892.9 million in revenue, and has provided optimistic guidance for FY2025.
Y Intercept Hong Kong Ltd Has $1.11 Million Holdings in Teleflex Incorporated $TFX
Y Intercept Hong Kong Ltd significantly reduced its stake in Teleflex Incorporated by 82.1%, ending up with 9,068 shares valued at approximately $1.11 million. This comes as Teleflex (NYSE: TFX) recently beat quarterly EPS expectations and provided strong FY2025 guidance. The company has a market capitalization of $4.61 billion, with institutional investors owning about 95.6% of the stock, and an average analyst rating of "Hold."
Montagu and Kohlberg Acquire Teleflex Medical OEM for $1.5 Billion
Montagu and Kohlberg have acquired Teleflex Medical OEM for $1.5 billion. Kirkland & Ellis, Ropes & Gray, and Matheson advised the acquirers, while Simpson Thacher advised Teleflex Incorporated. The article indicates that Montagu and Kohlberg are prominent middle-market private equity firms but restricts further details to members.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Teleflex Incorporated (TFX) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Teleflex Incorporated (TFX) following the abrupt departure of its Chairman, President, and CEO, Liam Kelly, on January 8, 2026. This announcement led to a significant 13.06% drop in Teleflex’s stock price. The firm is encouraging shareholders who purchased Teleflex securities to come forward and assist in the investigation, offering their services on a contingency fee basis.
Why One Fund Just Bet $4 Million on Teleflex Stock Despite a 42% One-Year Drop
Eos Management has disclosed a new $3.76 million stake in Teleflex (TFX), purchasing 30,831 shares despite the medical technology company's stock experiencing a 42% decline over the past year. This move is notable because Teleflex has underperformed the S&P 500 significantly and is facing operational uncertainties, including a narrowed revenue growth outlook and a leadership transition. The investment suggests confidence from Eos Management that Teleflex's recent challenges are already factored into its stock price and that its strategy to focus on higher-acuity hospital markets will lead to long-term growth and improved margins.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
Pomerantz LLP is investigating potential securities fraud claims against Teleflex Incorporated (TFX) after the company announced the immediate departure of its Chairman, President, and Chief Executive Officer, Liam Kelly, on January 8, 2026. This announcement led to a significant 13.06% drop in Teleflex's stock price. The law firm is advising investors who suffered losses to contact them regarding a potential class action lawsuit.
Teleflex Incorporated (NYSE:TFX) Receives Consensus Rating of "Hold" from Analysts
Analysts have given Teleflex Incorporated (NYSE:TFX) a consensus "Hold" rating based on reports from twelve brokerages, with an average 12-month price target of $141.88. The company recently exceeded quarterly EPS and revenue estimates, reporting $3.67 EPS against an expected $3.38 and revenues of $892.9 million, an increase of 19.4% year-over-year. Teleflex also provided FY2025 EPS guidance between $14.00 and $14.20, slightly above analyst expectations.
Teleflex Inc Is Quietly Running the Medical Device Game – Here’s What Wall Street Isn’t Tellin
Teleflex Inc is presented as a quiet but fundamentally strong medical device company, focusing on essential tools for hospitals rather than flashy consumer gadgets. The article highlights its "must-use" products, sticky customer base in healthcare, and focus on solid profitability as key investment considerations. It suggests TFX is a long-term "cop" for patient investors seeking stability over hype, despite not being a meme stock or viral sensation.
Needham upgrades Teleflex stock to Buy on divestiture plans
Needham has upgraded Teleflex (NYSE:TFX) stock from Hold to Buy, setting a price target of $138, citing the company's planned divestitures of its Acute Care, Interventional Urology, and OEM businesses for $2 billion. The firm anticipates Teleflex will use the $1.8 billion in after-tax proceeds for stock repurchases and debt reduction, with shares currently trading at an attractive valuation near a 52-week low. Needham expects investor recognition of future earnings potential and sustained mid-single-digit organic growth to drive the stock higher.
Teleflex Incorporated (TFX): Investor Outlook Highlights Potential 26.97% Upside
Teleflex Incorporated (TFX), a medical device company, shows a potential upside of 26.97% based on analyst target prices, despite recent profitability challenges. The stock's low Relative Strength Index (RSI) indicates it's oversold, while a low forward P/E ratio suggests undervaluation. Although recent EPS and ROE are negative, strong revenue growth and healthy free cash flow provide a positive outlook for the company.
Teleflex Incorporated $TFX Stake Raised by Cooke & Bieler LP
Cooke & Bieler LP has increased its stake in Teleflex Incorporated (NYSE:TFX) by 1.2% in the third quarter, bringing their total holdings to 1,220,637 shares valued at approximately $149.36 million. This makes Teleflex their 22nd largest holding, with institutional ownership of the company reaching 95.62%. Despite positive Q3 earnings that beat estimates, analysts have a "Reduce" consensus rating with an average target price of $142.43.
Wealth Enhancement Advisory Services LLC Grows Stock Position in Teleflex Incorporated $TFX
Wealth Enhancement Advisory Services LLC significantly increased its stake in Teleflex Incorporated during Q3, now owning 0.13% of the company. Despite institutional ownership of 95.62%, analyst sentiment for Teleflex remains weak, with a consensus "Reduce" rating and a price target of $142.43. Teleflex, however, recently reported strong Q3 earnings, beating estimates, and provided positive FY2025 guidance.
The Truth About Teleflex Inc.: Quiet Stock, Big Money Moves – Are You Sleeping On This?
This article examines Teleflex Inc. (TFX), a global medical technology company specializing in critical hospital devices. It suggests that while the internet is focused on AI, crypto, and EVs, Teleflex is a "quiet stock" making significant money due to the essential nature of its products. The piece highlights Teleflex's defensive healthcare nature, high-margin medical devices, and niche global presence as reasons for its appeal to long-term investors seeking stability and growth over quick, volatile gains.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
Pomerantz LLP is investigating potential claims of securities fraud against Teleflex Incorporated (NYSE: TFX) on behalf of its investors. This investigation follows a significant drop in Teleflex's stock price by 13.06% on January 8, 2026, after the company announced the immediate departure of its Chairman, President, and CEO, Liam Kelly. Investors who suffered losses are encouraged to contact Pomerantz LLP for more information.
Teleflex Incorporated (TFX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teleflex Incorporated (NYSE:TFX) following a significant drop in its stock price. This decline occurred after the departure of Liam Kelly as Chairman, President, and CEO on January 8, 2026. The firm is encouraging shareholders who purchased Teleflex securities to contact them to learn more about potential claims.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Teleflex Incorporated (TFX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased Teleflex Incorporated (NYSE:TFX) securities. This investigation follows the announcement on January 8, 2026, that Liam Kelly had departed as Teleflex's Chairman, President, and CEO, which led to a significant drop in the company's stock price. The law firm is encouraging affected investors to connect to assist with the investigation, with no direct cost to them as they operate on a contingency fee basis.
Teleflex Inc (TFX) Trading 3.01% Higher on Jan 22
Teleflex Inc (TFX) saw its shares rise by 3.01% in mid-day trading on January 22nd, with the stock closing at $106.06. Analyst forecasts indicate an average target price of $139.13 for TFX, suggesting a potential upside of 31.18% from its current price. GuruFocus estimates the stock's fair value (GF Value) at $285.13, implying an even larger potential upside of 168.84%.
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
Pomerantz LLP is investigating potential securities fraud claims against Teleflex Incorporated (NYSE: TFX) on behalf of its investors. This investigation follows a significant drop in Teleflex's stock price on January 8, 2026, after the company announced the immediate departure of its Chairman, President, and CEO, Liam Kelly. The law firm encourages affected investors to contact them regarding a potential class action lawsuit.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Teleflex Incorporated (TFX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Teleflex Incorporated (NYSE:TFX) following a significant drop in its stock price. This decline occurred after the immediate departure of Liam Kelly, Teleflex's Chairman, President, and CEO, on January 8, 2026. The firm is encouraging investors who purchased Teleflex securities to join the investigation into potential claims.
Teleflex stock hits 52-week low at 101.01 USD By Investing.com
Teleflex Inc. stock has hit a 52-week low of $101.01, reflecting a 42.55% decline over the past year and a 15.6% drop year-to-date, attributed to challenges in the medical technology sector and negative EPS. Despite current unprofitability, analysts anticipate a return to profitability this year with a forecasted EPS of $14.22, and deem the stock undervalued. Recent developments include the sale of several businesses for over $2 billion and a $1 billion share repurchase program, positively influencing analyst ratings.
Montagu and Kohlberg acquire Teleflex in $1.5bn carve out
Private equity firms Montagu and Kohlberg are acquiring Teleflex Incorporated's Teleflex Medical OEM business in a $1.5 billion carve-out transaction. The medical device manufacturer will operate as an independent company, leveraging decades of experience from the acquiring firms to accelerate growth and innovation. This move is part of a broader trend among medtech companies to optimize portfolios and focus on high-margin segments.
Teleflex stock hits 52-week low at 101.01 USD
Teleflex Inc. shares have hit a 52-week low of $101.01, reflecting a challenging year with a 42.55% decline over the past 12 months and a 15.6% year-to-date drop. Analysts, however, anticipate a return to profitability this year with a projected EPS of $14.22, and the stock is considered significantly undervalued. The company recently announced the sale of three businesses for $2.03 billion and a $1 billion share repurchase program, moves positively received by analysts like Wells Fargo, which raised its price target.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Teleflex Incorporated (TFX) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Teleflex Incorporated (NYSE:TFX) after the company announced the immediate departure of its Chairman, President, and CEO, Liam Kelly, on January 8, 2026. This news led to a significant drop in Teleflex's stock price, falling 13.06% ($16.52 per share) to $110.01. The firm is encouraging stockholders who purchased Teleflex securities to connect and assist with the investigation, offering representation on a contingency fee basis.
Why Teleflex (TFX) Is Down 8.7% After CEO Exit, Lower 2025 Outlook And Legal Scrutiny
Teleflex (TFX) experienced an 8.7% stock drop following the immediate departure of its CEO, Liam Kelly, and a trimmed 2025 revenue outlook. The company also faces a securities law investigation, raising concerns about its medical device portfolio and overall business direction. These events highlight execution risks and impact the investment narrative, despite the company's long-term projections for revenue and earnings growth.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Teleflex Incorporated (TFX) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Teleflex Incorporated (TFX) following a significant drop in its stock price. This decline occurred after the unexpected departure of Teleflex's Chairman, President, and CEO, Liam Kelly, on January 8, 2026. The law firm is encouraging investors who purchased Teleflex securities to join the investigation into potential claims.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX
Pomerantz LLP is investigating potential claims against Teleflex Incorporated (TFX) after the company's stock price dropped significantly following the immediate departure of its Chairman, President, and CEO, Liam Kelly. The law firm is advising investors who may have been affected by alleged securities fraud or other unlawful business practices to contact them.
Lobbying Update: $20,000 of TELEFLEX INCORPORATED lobbying was just disclosed
TELEFLEX INCORPORATED (TFX) recently disclosed $20,000 in lobbying expenditures for Q4 2025, focused on educating government stakeholders about their R&D capabilities supporting US service members. The article also details recent congressional stock trading, insider trading activity, significant hedge fund movements in TFX shares, and analyst price targets for the company.
Robeco Institutional Asset Management B.V. Raises Position in Teleflex Incorporated $TFX
Robeco Institutional Asset Management B.V. significantly increased its stake in Teleflex Incorporated (NYSE:TFX) by 2,365.5% in the third quarter, now owning 68,960 shares valued at approximately $8.44 million. This move comes as Teleflex beat Q3 EPS estimates and reported strong revenue growth, with institutional investors holding a substantial 95.62% of the company's stock. Despite a "Reduce" consensus analyst rating, the company offers a quarterly dividend and analysts expect further EPS growth for FY2025.
Teleflex CEO leaving company
Teleflex CEO Liam Kelly has left the company, with retired board member Stuart Randle stepping in as interim president and CEO. This leadership change comes as Teleflex undergoes a transformation, including the sale of three units for approximately $2 billion, aiming to become a more focused, higher-growth organization. The company also reduced its full-year guidance due to soft demand for heart devices, anticipating 2025 revenue between $3.27 billion and $3.28 billion.
Teleflex Appoints Stuart Randle as Interim CEO
Teleflex Incorporated has appointed Stuart Randle, a current board member, as interim President and CEO, following the departure of Liam Kelly. The company is actively searching for a permanent CEO and is entering a new phase focused on higher growth after selling certain businesses. Teleflex also updated its preliminary full-year 2025 revenue guidance downward due to softer demand and order delays.
Is Teleflex’s (TFX) Interim CEO Shift And Softer 2025 Guide Reframing Its Execution Story?
Teleflex (TFX) recently appointed Stuart Randle as interim CEO, replacing Liam Kelly, and simultaneously provided preliminary 2025 revenue guidance of approximately US$3.27 billion, which is slightly lower than previous expectations due to reduced demand and delayed orders. This leadership change and softer outlook are prompting questions about the company's near-term execution and the stability of demand in key product lines. The article suggests that investors will be watching how management addresses these challenges and integrates recent acquisitions.
Teleflex announces leadership transition as CEO Liam Kelly departs, cuts 2025 revenue guidance
Teleflex announced the immediate departure of its Chair, President, and CEO, Liam Kelly, and appointed Stuart Randle as interim CEO. This leadership change comes as Teleflex is transforming its business, having recently agreed to sell its Acute Care, Interventional Urology, and OEM businesses for over $2 billion. The company also cut its full-year 2025 revenue guidance due to softer demand for certain products and delayed purchase orders.
